Loading...
Please wait, while we are loading the content...
Similar Documents
Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report
| Content Provider | MDPI |
|---|---|
| Author | Luongo, Cristina Porcelli, Tommaso Sessa, Francesca Stefano, Maria Angela De Scavuzzo, Francesco Damiano, Vincenzo Klain, Michele Bellevicine, Claudio Matano, Elide Troncone, Giancarlo Schlumberger, Martin Salvatore, Domenico |
| Copyright Year | 2021 |
| Description | Anaplastic thyroid cancer (ATC) is a rare but aggressive thyroid cancer, responsible for about 50% of all thyroid cancer-related deaths. During the last two decades, the development of a multimodal personalized approach resulted in an increased survival. Here, we present an unusual case of a 54-year old woman with a paucicellular metastatic ATC, a rare variant of ATC, who was treated with a combination of surgery, radiation therapy and cytotoxic chemotherapy. More than two years later, when the disease was rapidly growing, a combination of lenvatinib and pembrolizumab induced a partial tumor response of lung metastasis that persisted over 18 months. Paucicellular ATC may initially show a less aggressive behavior compared to other histological ATC variants. However, over the time, its clinical course can rapidly progress like common ATC. The combination of lenvatinib and pembrolizumab was effective as a salvage therapy for a long period of time. |
| Ending Page | 5407 |
| Page Count | 7 |
| Starting Page | 5401 |
| e-ISSN | 17187729 |
| DOI | 10.3390/curroncol28060450 |
| Journal | Current Oncology |
| Issue Number | 6 |
| Volume Number | 28 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-12-16 |
| Access Restriction | Open |
| Subject Keyword | Current Oncology Endocrinology and Metabolism Anaplastic Thyroid Cancer Immunotherapy Tyrosine Kinase Inhibitors |
| Content Type | Text |
| Resource Type | Article |
